\
&
Contact us
\
&
Contact us
Published on | 6 years ago
ProgrammesIn the proposal of Horizon Europe, under Pillar II – “Global Challenges and Industrial Competiveness”, the Health cluster and its six intervention areas are described at an aggregated level (i.e. with no disease specifications, nor earmarked resources). This will be further detailed in the “strategic plan” and work programmes that are to be developed in a participatory manner.
All stakeholders, including civil society and the wider public, are invited to “Have your say on future objectives for EU-funded research and innovation” and contribute to the “strategic plan” and priorities of Horizon Europe’s first four years (2021-2024). You can participate by providing your input through the online survey (it takes approximately 20 minutes to respond). More information on the Commission’s proposal for Horizon Europe can be found here.
The before mentioned public online consultation will be open until the 6th of September 2019.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Civil Security Digital, Industry & Space Agro-Food, Environment
The European Innovation Council has launched a call to recruit independent experts of diverse innovative defence and dual-use technologies (as eg. maritime, medical, drones, financial expertise, ..). It is important for the EIC to have a solid batch of experts with a balanced national diversity. Note that, as a requirement and due to security sens... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
